Numerically better disease control rates (50% vs. 20%) and median survival (5.8 months vs. 3.9 months) were observed for KRAS wild-type (WT) vs. KRAS-mutated (MUT) pancreatic cancers. Here, KRAS is linked to familial pancreatic carcinoma.